Iovance Biotherapeutics, Inc. (IOVA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Iovance Biotherapeutics, Inc. (IOVA)
Go deeper and ask any question about IOVA
Company Performance
Current Price
as of Sep 13, 2024$10.34
P/E Ratio
N/A
Market Cap
$3.14B
Description
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Metrics
Overview
- HQSan Carlos, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerIOVA
- Price$10.34+9.30%
Trading Information
- Market Cap$3.14B
- Float81.42%
- Average Daily Volume (1m)6,245,580
- Average Daily Volume (3m)7,079,242
- EPS-$1.68
Company
- Revenue$32.77M
- Rev Growth (1yr)12,969.75%
- Net Income-$97.10M
- Gross Margin-18.13%
- EBITDA Margin-292.71%
- EBITDA-$91.05M
- EV$1.95B
- EV/Revenue59.60
- P/EN/A
- P/S89.86
Documents
SEC Filings
Earnings Calls